Mitochondrial damage

Mitochondrial damage refers to the structural and functional impairment of mitochondria, the double-membrane-bound organelles essential for cellular energy production through oxidative phosphorylation (OXPHOS). This pathological state is characterized by the loss of mitochondrial membrane potential, excessive generation of reactive oxygen species (ROS), and the depletion of adenosine triphosphate (ATP) (Lin & Beal, 2006, Nature). When severe, mitochondrial damage triggers the release of pro-apoptotic factors like cytochrome c into the cytoplasm, leading to programmed cell death (Galluzzi et al., 2012, Nature Reviews Molecular Cell Biology). It is a central driver in the progression of neurodegenerative diseases such as Parkinson's and Alzheimer's, as well as cardiovascular disorders and metabolic syndromes (Murphy & Hartley, 2018, Nature Reviews Drug Discovery). Although mitochondrial damage is a complex process rather than a single molecular target, therapeutic efforts focus on protecting mitochondrial integrity through agents that stabilize membranes, scavenge free radicals, or inhibit the opening of the mitochondrial permeability transition pore (mPTP) (Solesio et al., 2013, Journal of Biological Chemistry). Consequently, managing mitochondrial health is a primary objective in drug development for aging-related and chronic metabolic conditions.

Other names

Mitochondrial dysfunctionMitochondrial injuryMitochondrial oxidative stressMitochondrial membrane depolarizationMitochondriopathy

Therapeutic intervention involves inhibiting the mitochondrial permeability transition pore (mPTP), scavenging mitochondrial reactive oxygen species, stabilizing the mitochondrial inner membrane (e.g., via cardiolipin binding), or enhancing mitochondrial biogenesis and mitophagy pathways.